Treatment-naive patients with HCV G@/@ infection were randomized to twice-daily danoprevir/r @/@ mg ( A , n = @ ) ; @/@ mg ( B , n = @ ) ; or @/@ mg ( C , n = @ ) plus P/R for @ weeks ; twice-daily danoprevir/r @/@ mg ( D , n = @ ) plus P/R for @ or @ weeks ; or P/R alone ( E , n = @ ) for @ weeks .